相关实验视频
Updated: Jun 11, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
309
临床医生的小儿抗肥胖药物指南
Wesley P Dutton1, Nina Paddu2, Amy Braddock3
1Harvard Medical School, Massachusetts General Hospital, Weight Center at Massachusetts General Hospital, Boston, MA, USA.
Pediatric clinics of North America
|September 29, 2024
概括
现在建议高效的抗肥胖药物 (AOM) 适用于12岁及以上的肥胖青少年. 这些药物应该补充生活方式的改变,以改善体重管理结果.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 药物治疗 药物治疗
- 肥胖医学 肥胖医学
背景情况:
- 肥胖是青少年的重大健康问题.
- 最近的进展引入了高效的抗肥胖药物 (AOM).
- 2023年美国儿科学会的指导方针支持青少年肥胖的药物治疗.
研究的目的:
- 提供关于将AOM纳入儿科临床实践的最新情况.
- 为青少年使用AOM提供实用指导和临床珍珠.
- 支持临床医生实施减肥药物治疗.
主要方法:
- 关于青少年肥胖的AOM当前文献和指导方针的审查.
- 对AOM使用的临床建议的综合.
- 强调实际应用和管理策略.
主要成果:
- 建议使用AOM作为12岁及以上肥胖青少年的生活方式治疗的辅助剂.
- 指导方针强调考虑药物指示,风险和益处.
- 整合到实践中需要仔细考虑患者特定的因素.
结论:
- 抗肥胖药物对儿科临床医生来说是一个有价值的工具.
- 有效地整合AOM可以增强肥胖治疗和改善患者的结果.
- 实用提示对于在临床环境中成功实施至关重要.
相关概念视频
Obesity
392
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
392
Prescription, Nonprescription and Orphan Drugs
704
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
704
Diabetes: Management and Pharmacotherapy
243
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
243
Oral Hypoglycemic Agents: Biguanides and Glitazones
181
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
181
Oral Hypoglycemic Agents: Glinides
143
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
143
Insulin: Dosing Regimen and Adverse Effects
155
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
155

